Concerns exist about GLP-1 receptor agonists causing substantial weight loss and increasing the risk of ketoacidosis or hypoglycemia, Hui Shao , M D, PhD , associate professor in the Hubert department of global health and Emory Global Diabetes Research Center at Emory University Rollins School of Public Health, and colleagues wrote
The compound is not a therapeutic substance, food product or cosmetic material and cannot be repurposed or relabeled for such use
A partir de esa base, KLOW, tambin denominado GLOW-80, surge como una extensin que suma el KPV para incorporar el eje antiinflamatorio de la melanocortina, ampliando el espectro de vas investigables
[16] [18] The addition of glucagon receptor agonism introduces further safety considerations requiring evaluation in Phase 3 trials, including potential effects on heart rate, blood pressure, and hepatic glucose output